Skip to main content

Venture Day with Viva Biotech & Venture

When:

May 15, 2019 8:00 amMay 15, 2019 5:00 pm

Where:

Biocom
10996 Torreyana Road
San Diego, CA 92121


May 15th, the Viva Biotech & Venture team will be in San Diego to meet with local biotech companies, institutions and entrepreneurs

Viva Biotech & Venture (ViV) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and early development of biotech startups across all indications and drug types. It’s during these early stages, we can nurture and accelerate a startup’s seeding and growth from an idea into clinical programs.

Since our inception in 2016, we have continued to evolve and optimize our investment model as we try to ensure the success of our portfolio companies. In addition to cash, CRO services, administrative, and operational backing, and etc., we established a dual track in-person support team through our “Venture Partners” and “Business Partners.” This support team gives the founders crucial access to advice and resources from both a scientific perspective as well as a business and compliance perspective. Additionally, ViV can provide solid support in BD, financial advising, and more for our founders as part of our baseline services. Beyond Viva’s in-house capabilities, we are building a drug development supplier network including organizations such as CMCs, CMOs, or clinical CROs.

As of early 2019, ViV has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. Our seed or A-round funding is typically in the range of $500K – $5 Million.

ViV investment focuses primarily on innovative therapeutics. We assess investment opportunities based on four dimensions:
  1. We insist the founders have high integrity with a successful track record of building a company and/or developing a drug.
  2. The “idea” needs to be innovative
  3. There must be a true unmet medical need.
  4. We invest in opportunities with significant market potential 5-10 years in the future.

How to Apply:

If you are working on innovative therapeutics in the areas listed above and interested in meeting with the Viva Biotech & Venture Team, please send over a one-page non-confidential executive summary or corporate deck to Oscar Rodarte at orodarte@biocom.org by May 1st for consideration.

*Please note that this is an opportunity to apply to meet one-on-one with the ViV team to discuss your company, pipeline and technologies. The event is not open to public; the one-on-one meetings are by invitation only.


In Partnership with:

User-added image


About Viva Biotech Holdings


Viva Biotech operates a leading structure-based, integrated drug discovery platform. We provide drug discovery services to our biotechnology and pharmaceutical customers worldwide. Our services cover the full spectrum of our customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Our patented core technologies, which enable us to effectively shorten the average time required for lead generation, are widely recognized by our customers.

  • Viva Team
    User-added image

    Cheney Mao, Ph.D. Founder, Chairman, Chief Executive Officer, and Executive Director

    Dr. Chen (Cheney) Mao is the Chairman, Chief Executive Officer, and an Executive Director of our Company. He is primarily responsible for the overall strategic planning and business development of the Group. Dr. Mao has over 20 years of experience in the CRO industry.Dr. Mao obtained his bachelor’s and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute. He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.


    User-added image

    Dr. David Xu, Chief Business Officer, Viva Biotech & Venture

    Dr. David Xu has over 20  years of pharma experiences in drug development, sales and marketing. He is currently the CBO at Viva Biotech, responsible for the investment and incubation business, including project search and evaluation, post-investment management and exit. Prior to joining Viva, Dr. Xu was a group VP at Zhejiang Jiuzhou Pharma, responsible for building up the Pharma business.  Before returning to China, Dr. Xu was Head of Marketing and New Product Planning at Purdue Pharma(US).  Dr. Xu started his career at Novartis and held various positions in Development and Commercial, including Head of Specialty Products Franchise at SANDOZ, Inc. and Head of Suzhou Novartis R&D center. 


    User-added image

    Mrs. Yinghong Gao, Associate Business Partner, Viva Biotech & Venture

    Yinghong is currently an Associate Business Partner at Viva Biotech & Venture and the Executive Director of Business Development for Viva’s CRO business. She has broad business development experience ranging from early drug discovery to pre-clinical and clinical development. Prior to that, she was an integral team member of target selection, licensing & scientific network of MerckMillipore, responsible for lead evaluation and new product introduction. She started her drug discovery career as a medicinal chemist with additional expertise in computer aided drug design, working at biotech companies including Cytel Corporation, Neurocrine Biosciences and Arena Pharmaceuticals with increasing responsibilities. Her successful drug discovery track record is evidenced by over 30 publications and patents, multiple IND clinical candidates in different therapeutic areas and her indelible contributions to the discovery of Elagolix which led to the successful partnership with AbbVie and the recent FDA approval in 2018.  She holds a MSc. Degree from Chinese Academy of Sciences in physical chemistry and a MSc. Degree from Tulane University in organic chemistry.